Iterum Therapeutics Announces CMO Transition and Consultant Role
Company Announcements

Iterum Therapeutics Announces CMO Transition and Consultant Role

An update from Iterum Therapeutics Plc (ITRM) is now available.

Sailaja Puttagunta M.D. will step down as Chief Medical Officer of Iterum Therapeutics plc on May 31, 2024, for personal reasons, not due to any conflict with the firm. She will continue to assist as a consultant during the regulatory review of the company’s new drug application. Dr. Steven Aronin will take over her responsibilities in leading the company’s development and regulatory activities.

For an in-depth examination of ITRM stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyIterum Therapeutics commences rights offering
GlobeNewswireIterum Therapeutics Commences Rights Offering
GlobeNewswireIterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!